Neuro-Oncology News

The combination of intratumoral DNX-2401 and pembrolizumab appeared safe and provided “notable survival benefits” for select patients with recurrent glioblastoma, according to a study published in Nature Medicine.

In this video, Patrick Wen, MD, professor of neurology at Harvard Medical School and director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute, discusses novel and experimental treatments for brain cancer.

In this video, Patrick Wen, MD, professor of neurology at Harvard Medical School and director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute, discusses current challenges and opportunities in glioma treatment.

In this video, Patrick Wen, MD, professor of neurology at Harvard Medical School and director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute, discusses current challenges and opportunities in glioma treatment.

In this video, Patrick Wen, MD, professor of neurology at Harvard Medical School and director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute, discusses how diagnostic techniques for brain cancer are evolving.

In this video, Patrick Wen, MD, professor of neurology at Harvard Medical School and director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute, discusses promising new brain cancer treatments.

The FDA announced several regulatory actions the past few weeks.

May is Brain Cancer Awareness Month.

Advances in pediatric cancer research and treatment over the past 50 years have led to dramatic improvements in survival outcomes for this vulnerable population.

The addition of disulfiram and copper to chemotherapy did not result in a significant survival benefit for patients with recurrent glioblastoma, according to data published in JAMA Network Open.